2010/06/24

Agapurin Retard

Composition, structure and packing

Long-acting tablets, coated white, round, biconvex.

1 tab. pentoxifylline 400 mg.

Excipients: eudragit RS PO, eudragit RS 100, eudragit RL 100, talc, polyvidone K25, calcium stearate, magnesium stearate.

The composition of the shell: E macrogol 6000, magnesium stearate. Long-acting tablets, coated white, round, biconvex.

1 tab. pentoxifylline 600 mg.

Excipients: eudragit RS PO, eudragit RL PO, talc, polyvidone K25, magnesium stearate. The composition of the shell: E macrogol 6000, eudragit E 12.5%, magnesium stearate, talc.

Clinico-pharmacological group: The drug, improves microcirculation. Angioprotectors.

Pharmacological action

The drug, which improves microcirculation with angioprotective action. It is a derivative of xanthine. Has vasodilator effect, improves blood rheology. Improves flexibility of red blood cells, reduces blood viscosity, improve microcirculation and tissue perfusion.

Pharmacokinetics

After receiving the drug inside the maximum concentration of pentoxifylline in plasma is achieved within 2-4 hours from the retarded form of pentoxifylline is released slowly. The distribution is uniform. Provided in the form of metabolites, mainly via the kidneys (94%) and in small amounts through the intestine (4%), about 2% is unchanged.

Statement
Violations of peripheral arterial and venous circulation, including the background of atherosclerosis, diabetes, obliterative endarteritis;
Violations of peripheral arterial and venous circulation against the background of atherosclerosis, diabetes and inflammatory processes (including in intermittent claudication caused by atherosclerosis, diabetic angiopathy, obliteriruyushim endarteritis);
violation of trophic (post syndrome, varicose ulcers, gangrene, frostbite);
angionevropatii (paresthesia, acrocyanosis, Raynaud's disease);
ischemic cerebral circulatory disorders (including cerebral atherosclerosis);
state after ischemic or hemorrhagic stroke;
circulatory eye (acute and chronic insufficiency of blood supply and vascular mesh eye membranes)
acute functional disorders of the inner ear.

Dosage regimen

Agapurin retard usually prescribed to 400 mg 2 times a day.

The drug should be taken after meals, do not chew, do not crush and drink a small amount of liquid.

Side effect

On the part of the digestive tract: possible nausea, vomiting, abdominal pain and a feeling of heaviness in the stomach.

Since the cardiovascular system: dizziness and feeling of warmth to the face of the tide observed at about 4-6% of cases.

Allergic reactions: seldom - itching, rash.

Contraindications
Acute myocardial infarction;
profuse bleeding;
acute hemorrhagic stroke;
Pregnancy
lactation.

Cautions

If hypotension and lability of blood Agapurin retard can cause a sharp decrease in blood pressure and in rare cases, angina symptoms, so treatment should be under the control of blood pressure. Agapurin can be used in conjunction with cardiac glycosides in patients with decompensated heart failure. In appointing Agapurina retard in patients with diabetes need correction dose of insulin or other antidiabetic funds, because may develop severe hypoglycemia.

Overdose

Symptoms: hypotension, convulsions, lethargy, loss of consciousness, agitation, fever.

Treatment: gastric lavage, followed by oral administration of activated charcoal, symptomatic treatment (including measures to maintain respiration and blood pressure).

Drug Interactions

At the same time appointing Agapurina retard and antihypertensive drugs may enhance their action. At the same time appointing a sympatholytic, ganglion blocking agents and vasodilators may decrease blood pressure.